Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update

About this update from Opus Genetics, Inc.

Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ETUpcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026LCA5 Accepted to FDA’s Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal TrialRDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 MonthsCash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update. “With encouraging momentum across both our LCA5 and BEST1 gene therapy programs, Opus Genetics is entering a defining stretch where we believe our precision targeted approach can reshape what’s possible for patients with inherited retinal diseases,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “Our upcoming BEST1 Cohort 1 clinical data and June R&D Science Forum will provide key opportunities to showcase the depth and maturity of our science and pipeline. Backed by a strong balance sheet and disciplined capital strategy, we are well-positioned to advance our lead programs toward pivotal trials, and accelerate our earlier‑stage RDH12, MERTK, and RHO programs into the clinic.”Pipeline UpdatesResearch & Development (R&D) Science ForumOpus Genetics plans to host an R&D Science Forum on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET, with management and key opinion leaders (KOLs) highlighting earlier-stage gene therapy programs entering clinical testing and IRD global market opportunities. Registration for the event will be available on the Events page of the Opus Genetics website.OPGx-BEST1Enrollment completed in Cohort 1 of the Phase 1/2 trial (BIRD-1) including participants with both dominant and recessive forms of BEST disease, with the final participant scheduled for dosing this month.Baseline demographics were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026...

View stock analysis, news, and events for Opus Genetics, Inc.